Press releases

Promethera® Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D


Total amount raised in the Series D reaches €47.2 Million.

Mont-Saint-Guibert, Belgium, and Tokyo, Japan, December 16, 2019 – Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the addition of €7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures. MEDIPAL HOLDINGS CORPORATION, the family office Six Snow, a Japanese private investor and a Belgian private investor also contributed to the extension. Promethera® will use the proceeds from the financing to further advance the company’s clinical programs in Non-alcoholic steatohepatitis (NASH) and Acute-on-Chronic Liver Failure (ACLF), as well as to accelerate Promethera’s growth in the Asian markets. The company plans to initiate clinical trials outside Europe in its two lead indications, NASH and ACLF, during the course of 2020.

“The additional investment by Sony Innovation Fund by IGV and Pegasus Tech Ventures continues to acknowledge the potential of our HepaStem™ technology,” said John Tchelingerian, PhD, President and Chief Executive Officer of the Promethera® Group. “With the additional funds provided by the Series D expansion, Promethera plans to further solidify its position as the leading drug development organization in cell-based therapies and regenerative medicines targeting severe liver disorders.”

Mr. Gen Tsuchikawa, CEO at Innovation Growth Ventures (IGV) added, “We decided to invest in Promethera® due to the company’s track record, their global presence, and their promising development programs in areas with significant unmet medical need. Promethera®’s management has steadily advanced the company’s capabilities in stem cell therapeutics for liver diseases and we are happy to invest during this stage of impressive growth.”

Over the course of the past 18 months, Promethera® has established a rapidly growing organization in Japan with a local branch office in Tokyo that acts as a cornerstone for the company’s expansion strategy in Asia. Through a series of financing transactions, Promethera® has attracted a number of domestic institutional investors in Asia such as Mitsui & Co. Global Investment, Mitsubishi UFJ Capital Co., Ltd., Shinsei Corporate Investment, Cell Innovation Partners, Shinsei Capital Partners, Korea Investment Partners, Mirae Asset Capital, Beyond Next Ventures, Ci:z Investment LLP and Co-High/CMBCC. The investor base is further complemented by a group of renowned European venture capital firms and family offices as well as strategic investors and corporate venture companies, namely ITOCHU Corporation, Shibuya Corporation, LifeLiver, Sosei Corporate Venture Capital and MEDIPAL HOLDINGS CORPORATION.

READ FULL PRESS RELEASE HERE